Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.

Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.

Protagonist Therapeutics Announces $300M Buyback Plan

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

Ascentage Pharma Stock Could More Than Double: Analyst

William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.

Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s